Thomas Pålsson

Thomas has an extensive experience from the life science sector during the last 20 years. He has been CFO at Arexis (merged with Biovitrum), worked actively as business controller in Albireo (AstraZeneca spin-off now listed on Nasdaq main list) and previously CFO at Integrum (Listed on First North (SE)).